Cardioxyl Pharmaceuticals

Clinical stage biopharmaceutical company

Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease...

Founded in 2005
Total money raised: $57.5M

27517 Exchange East, Suite 212
1450 Raleigh Road

Chapel Hill
Chapel Hill

Phone: (919) 869-8585

Christopher A. Kroeger President and CEO
John Reardon Chief Scientific Officer
Robert Garland director
M. James Barrett Board Member

November, 2012

Cardioxyl Pharmaceuticals raised $28M in a Series B round from OrbiMed Advisors, New Enterprise Associates, The Aurora Funds, and Osage University Partners

Cardioxyl Pharmaceuticals Raises $28 Million in Series B Financing Led by OrbiMed Advisors

August, 2010

Cardioxyl Pharmaceuticals raised $15M in unattributed round


December, 2006

Cardioxyl Pharmaceuticals raised $14.5M in a Series A round from The Aurora Funds and New Enterprise Associates

Cardioxyl Raises 14.5MM Series A Financing


Cardioxyl Pharmaceuticals was founded in 2005